Cullinan Oncology LLC
$ 10.58
0.76%
04 Dec - close price
- Market Cap 625,027,000 USD
- Current Price $ 10.58
- High / Low $ 10.79 / 10.08
- Stock P/E N/A
- Book Value 7.64
- EPS -3.32
- Next Earning Report 2026-03-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.26 %
- ROE -0.40 %
- 52 Week High 13.60
- 52 Week Low 5.68
About
Cullinan Oncology LLC is an innovative biopharmaceutical company based in Cambridge, Massachusetts, dedicated to advancing targeted oncology and immuno-oncology therapies to improve outcomes for cancer patients. With a robust pipeline of therapeutic candidates addressing significant unmet needs in oncology, Cullinan is at the forefront of transforming cancer treatment through cutting-edge science and strategic partnerships. The company's commitment to pioneering research positions it as a vital player in the dynamic landscape of oncology therapeutics, aiming to bring forth impactful solutions for various cancer types.
Analyst Target Price
$27.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-06 | 2025-08-07 | 2025-05-13 | 2025-03-12 | 2024-11-06 | 2024-08-08 | 2024-05-15 | 2024-03-14 | 2023-11-08 | 2023-08-10 | 2023-05-11 | 2023-03-09 |
| Reported EPS | -0.77 | -1.19 | -0.74 | -0.73 | -0.69 | -0.75 | -0.86 | -0.54 | -0.91 | -0.82 | -1.42 | -0.59 |
| Estimated EPS | -0.95 | -0.82 | -0.99 | -0.7423 | -0.81 | -0.73 | -0.99 | -0.96 | -0.92 | -0.97 | -0.98 | -0.66 |
| Surprise | 0.18 | -0.37 | 0.25 | 0.0123 | 0.12 | -0.02 | 0.13 | 0.42 | 0.01 | 0.15 | -0.44 | 0.07 |
| Surprise Percentage | 18.9474% | -45.122% | 25.2525% | 1.657% | 14.8148% | -2.7397% | 13.1313% | 43.75% | 1.087% | 15.4639% | -44.898% | 10.6061% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-05 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.8739 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CGEM
2025-11-16 08:52:00
This article provides an AI-driven analysis for Cullinan Oncology Inc. (NASDAQ: CGEM), highlighting a positive near-term sentiment that may shift, a lack of clear price positioning, and elevated downside risk. It details three distinct trading strategies (Position Trading, Momentum Breakout, Risk Hedging) and multi-timeframe signal analysis to guide investors. The report emphasizes the role of price-sensitive allocations and institutional trading strategies for optimizing risk and returns.
2025-11-03 09:11:00
Cullinan Therapeutics (NASDAQ: CGEM) announced promising Phase 1 data for CLN-049 in relapsed/refractory AML and MDS, showing significant anti-leukemic activity and a manageable safety profile. The drug achieved a 69% Overall Response Rate (ORR) and 31% Composite Complete Response (CRc) at the highest dose, with responses observed across varying FLT3 mutational statuses, including TP53-mutated AML patients. Cullinan will present updated results at the 67th ASH Annual Meeting in December 2025 and will host an investor event to discuss the findings.
2025-10-25 11:01:00
Cullinan Therapeutics will present new preclinical data for CLN-978, its bispecific T cell engager, at ACR Convergence 2025, demonstrating rapid and deep B cell depletion in both in vitro and in vivo models relevant to multiple autoimmune diseases. The data supports CLN-978's potential to modify the underlying pathophysiology of diseases like rheumatoid arthritis, Sjögren's disease, and systemic lupus erythematosus by robustly depleting target B cells. The company is currently advancing CLN-978's global clinical development through its OUTRACE studies across these three indications.
2025-10-17 05:30:02
This article provides an AI-driven analysis of Cullinan Oncology Inc. (NASDAQ: CGEM), highlighting a strong near and mid-term sentiment but a weak long-term outlook with elevated downside risk. It presents three distinct trading strategies (Position, Momentum Breakout, Risk Hedging) and multi-timeframe signal analysis, including support and resistance levels. The analysis also emphasizes the importance of current signals for positioning and risk parameters.
2025-10-16 06:15:03
Cullinan Therapeutics (NASDAQ:CGEM) saw its stock rise by 11.5% recently. This increase follows several analyst reports setting new price targets, insider stock transactions by Lynx1 Capital Management Lp, and institutional investors adjusting their positions in the company. Cullinan Therapeutics is a biopharmaceutical company focused on developing oncology therapies, with several candidates in various phases of clinical trials.
2025-10-13 16:46:34
Cullinan Therapeutics Inc. and Taiho Oncology Inc. announced new data from the REZILIENT2 study of zipalertinib, showing efficacy in brain metastases for advanced non-small cell lung cancer (NSCLC) patients with specific EGFR mutations. The drug demonstrated an intracranial objective response rate of 31.3% and a disease control rate of 68.8% in measurable CNS disease, with a median intracranial duration of response of 8.1 months. Zipalertinib was well-tolerated, with manageable adverse events, and CGEM stock saw a price increase following the announcement.
